Table 1.
Patients' demographic and clinical characteristics.
| n a | 50 |
| Number of patients | 44 |
| CD, n (%) | 44 (100) |
| Age at induction, years (median, IQR) | 33.5 (25.7–39.2) |
| Age at diagnosis, years (median, IQR) | 27 (19–36) |
| Disease duration, years (median, IQR) | 2 (1–7.5) |
| Male/female ratio | 0.91 |
| Smoking at induction, n (%) | 12 (27.2) |
| Past smoker, n (%) | 6 (13.6) |
| Previous surgery, n (%) | 10 (22.7) |
| Weight at induction (median, IQR) | 65 (59–82.5) |
| Comorbidities, n (%) | 21 (47.7) |
| Concomitant immunomodulator therapy, n (%) | 12 (27.2) |
| Disease location, n (%) | Ileal - 22 (50) Ileo-colonic - 22 (50) |
| Disease behavior, n (%) | Inflammatory - 22 (50) Stricturing - 14 (31.8) Fistulizing - 8 (18.2) |
| Perianal involvement, n (%) | 12 (27.2) |
| CD upper GI involvement, n (%) | 12 (27.2) |
| Extra-intestinal manifestations, n (%) | 23 (52.2) |
| Previous adalimumab therapy, n (%) | 3 (6) |
| Previous anti-TNF therapy, n (%) | 14 (32.5) |
| Previous immunomodulator therapy, n (%) | 26 (60.4) |
| Once weekly adalimumab therapy | 10 (20) |
CD: Crohn's disease; GI: gastrointestinal; IQR: interquartile range; TNF: tumor necrosis factor.
a
Number of events of adalimumab measurement within 30 days of intestinal ultrasound.